Regulation (EU) 2017/745 gives manufacturers more than one way to demonstrate conformity, and the route choice in Article 52 is not three independent menu items. Annex IX is a combined quality-management-system and technical-documentation assessment, and it is the default most manufacturers use. Annex X is type examination — and it is not a stand-alone route at all. It only becomes one once paired with Annex XI. Treating the three annexes as interchangeable options is where conformity assessment strategy goes wrong before a notified body is even involved.

Class sets the menu before route does

Conformity assessment route is downstream of classification, not a separate decision. A device's class under Annex VIII's classification rules determines which Article 52 procedures are even available, and how much of each one applies. Most Class I manufacturers never reach a notified body at all. Class IIa, IIb, and III manufacturers do, and for them the real decision is which combination of annexes the notified body will assess against — a choice worth making deliberately rather than defaulting to whatever a notified body's scope happens to offer first.

3
Conformity assessment routes Article 52 sets out: Annex IX, or Annex X paired with Annex XI.
Annex IX
Combined QMS assessment (Chapter I) and technical documentation review (Chapter II) — the default route.
0
Routes where Annex X works alone. It requires Annex XI Part A or Part B to complete it.

What each annex actually assesses

The three annexes examine different things, which is why swapping between them changes more than the paperwork volume:

  • Annex IX — QMS plus technical documentation. Chapter I assesses the manufacturer's quality management system, covering both design and production. Chapter II is the notified body's review of the technical documentation itself, examined fully for Class III devices and on a representative sampling basis for Class IIa and IIb.
  • Annex X — type examination. The notified body examines a representative sample (the "type") and certifies that it meets MDR requirements. This confirms the design is sound but says nothing about the manufacturer's ongoing production quality — which is exactly what it does not authorize on its own.
  • Annex XI Part A — production quality assurance. The notified body audits the manufacturer's quality system for manufacturing and final inspection, not design. Used after Annex X has already addressed the design side.
  • Annex XI Part B — product verification. Rather than auditing a quality system, the notified body examines or tests individual devices or statistically representative samples from production batches.
Annex X answers whether the design works. It was never built to answer whether the factory can reproduce it — that is Annex XI's job, every time. Why the pairing isn't optional

Where manufacturers get the route wrong

The most common error is not picking the wrong annex outright — it is treating Annex IX as pure paperwork once a notified body has accepted it, rather than as an ongoing relationship where the audit cadence and technical documentation sampling continue for the life of the certificate. The second most common error is assuming Class I status means no regulatory scrutiny at all. Article 52(7) self-declaration still requires a complete Annex II and III technical file; it only removes the notified body step for devices that are non-sterile, carry no measuring function, and are not reusable surgical instruments. Sterile Class I devices, measuring Class I devices, and Class Ir reusable surgical instruments all keep a notified body — just one scoped narrowly to the exception that triggered it.

Questions to settle before committing to a route
  1. Has the device's class actually been confirmed under Annex VIII, not assumed from a prior directive-era classification?
  2. If Class I, does a sterility, measuring-function, or reusable-surgical-instrument exception apply that still requires narrow notified body involvement?
  3. For Class IIa/IIb/III, is Annex IX's representative-sampling technical documentation review actually sufficient, or does a design-heavy device justify the Annex X/XI design-scrutiny path?
  4. Does the chosen notified body's designation scope actually cover the annex combination being proposed?

None of this is a one-time decision filed away after initial certification. Conformity assessment route interacts with everything downstream of it — audit frequency, technical documentation update cadence, and how a gap assessment should even be scoped before a notified body transfer or a significant design change. Getting the route right at the outset, grounded in the device's actual class and design maturity rather than a notified body's default quote, is cheaper than renegotiating it after a nonconformity.

Frequently asked questions

What are the main conformity assessment routes under EU MDR?

Article 52 points manufacturers to Annex IX (quality management system assessment plus technical documentation review), or a combination of Annex X (type examination) with Annex XI (production quality assurance or product verification). Annex IX is the default most manufacturers use; the Annex X plus XI pairing is an alternative available mainly to higher-class devices.

Can a manufacturer use Annex X on its own?

No. Annex X type examination confirms that a representative sample of a device meets MDR requirements, but it does not by itself authorize placing the device on the market. It must be combined with Annex XI Part A (production quality assurance) or Part B (product verification) to form a complete route.

Do Class I devices need a notified body under MDR?

Generally no. Under Article 52(7), manufacturers of most Class I devices self-declare conformity based on their own Annex II and III technical documentation, without notified body involvement. The exceptions are sterile Class I devices, Class I devices with a measuring function, and reusable surgical instruments (Class Ir), where a notified body reviews only the aspects relevant to that exception.

Sources & further reading

  1. Regulation (EU) 2017/745, Articles 51-52 and Annexes VIII-XI. eur-lex.europa.eu
  2. European Commission. MDCG-endorsed guidance documents on the MDR. health.ec.europa.eu

This article is provided for general informational purposes and reflects the regulatory landscape as of October 2026. It is not legal or regulatory advice. Confirm current conformity assessment requirements with your notified body or qualified counsel before acting.